NAVIN FLUORINE Results Analysis-Q4FY26

Operating Revenue for Q4FY26 is Rs. 938 Crs., 33.78% growth YoY, Total Income is Rs. 955 Crs., 34% growth YoY, Gross Profit is Rs. 550 Crs., 44.7% growth YoY, EBITDA is Rs. 321 Crs., 79.7% growth YoY, EBITDA Margin is 34.25% improved by 875 Basis points YoY, PBT Rs. 282 Crs. 122.25% growth YoY, PAT Rs. 213 Crs. 123.9% growth YoY. On QoQ basis Op. Revenue is up by 5.08%, Total Income is up by 5.22%, Gross Profit is up by 4.76%, EBITDA is up by 4.42%,, PBT is up by 18.48% and PAT is also up by 14.68%. 1) HPP (High Performance Products / refrigerants & fluorochemicals) : • Q4 revenue: INR 393 cr (+20% YoY) driven by “improved realization and volume growth.” • AHF plant: “successfully commissioned and commercial supplies have commenced during the last quarter.” 2) Specialty Chemicals (incl. MPP) • Q4 revenue: INR 360 cr (+39% YoY) from “strong execution in both existing and new molecules,” with “scale up in ongoing products supported by customer confidence and long-term contracts.” • Dahej MPP debottlenecking: progressing; target commissioning Q3 FY27. 3) CDMO (pharma & specialty) • Q4 revenue: INR 186 cr (+61% YoY); mix described as “balanced mix of early, late-stage and commercial molecules” across oncology, respiratory, cardiovascular, neurology, animal health. • Portfolio breadth: management indicated ~50–55 molecules, “half… in late-stage commercial and half… in early stages.”